Загрузка...
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
OBJECTIVE: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia. This study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad in combination with febuxostat in adults with gout. METHODS: The phase I...
Сохранить в:
| Опубликовано в: : | RMD Open |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5892780/ https://ncbi.nlm.nih.gov/pubmed/29657831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2018-000647 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|